Avidity Biosciences Inc
RNAM
Kedudukan dalam Saham
#2082
Avidity Biosciences, Inc. is at the forefront of developing a novel class of... Avidity Biosciences, Inc. is at the forefront of developing a novel class of oligonucleotide-based therapies, known as Antibody Oligonucleotide Conjugates (AOCs). Utilizing its proprietary AOC platform, the company engineers treatments that strategically merge the targeted delivery capabilities of monoclonal antibodies with the precise action of oligonucleotide-based therapeutics. This innovative method aims to reach cell and tissue types previously inaccessible to treatment, thereby more effectively addressing the fundamental genetic causes of various diseases. The company was established on November 13, 2012, by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick, and its main office is located in San Diego, California.
Harga Saham
$71.34
Disegerakkan terakhir: 2026-03-03
Modal Pasaran
$9.84B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
-
Negara
US
Perdagangan Avidity Biosciences Inc (RNAM)
Kategori
Healthcare
Bilangan saham terbitan bagi Avidity Biosciences Inc (RNAM)
Bilangan saham terbitan setakat October 2026: 0
Menurut laporan kewangan terkini dan harga saham Avidity Biosciences Inc, bilangan saham terbitan semasa ialah 0. Pada akhir October 2026, syarikat mempunyai 0 saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk Avidity Biosciences Inc (RNAM) dari 2018 hingga 2026
Saham terbitan pada akhir setiap tahun
| Tahun | Saham Terbitan | Ubah |
|---|---|---|
| 2025 | 137.71M | 23.42% |
| 2024 | 111.58M | 52.83% |
| 2023 | 73.01M | 39.97% |
| 2022 | 52.16M | 25.91% |
| 2021 | 41.43M | 91.24% |
| 2020 | 21.66M | -42.27% |
| 2019 | 37.53M | 0.04% |
| 2018 | 37.51M | 0.00% |
Saham terbitan bagi syarikat atau pesaing yang serupa
| Syarikat | Saham Terbitan | Perbezaan | Negara |
|---|---|---|---|
| 253.90M | - |
US
|
|
| 396.00M | - |
US
|
|
| 478.91M | - |
AU
|
|
| 62.19M | - |
NL
|
|
| 0.00 | - |
BE
|
